No results for ‘’
Venus Remedies Ltd
₹1616.30
(0.49%)
Thu, 17 Sept 2026, 09:41 am
Health Technology
Pharmaceuticals: Major
24.5KVenus Remedies Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 17.83 | 13.83 | 8.50 | 2.86 | 5.51 | 3.99 | 3.21 | 4.73 | 4.52 | 29.56 | 59.80 | 14.23 | 0 | 0 | 0 | 5.49 | 8.82 | 8.15 | 15.31 | 8.84 |
| Price to book ratio | 9.04 | 6.37 | 3.68 | 0.91 | 1.27 | 0.78 | 0.52 | 0.67 | 0.61 | 0.33 | 0.23 | 0.31 | 0.22 | 0.12 | 0.09 | 0.85 | 0.82 | 0.47 | 0.89 | 0.71 |
| Price to sales ratio | 3.40 | 2.47 | 1.41 | 0.47 | 0.69 | 0.51 | 0.37 | 0.59 | 0.54 | 0.33 | 0.24 | 0.31 | 0.22 | 0.13 | 0.08 | 0.63 | 0.60 | 0.39 | 0.74 | 0.62 |
| Price to cash flow ratio | 32.86 | 14.60 | 15.94 | 6.62 | 6.88 | 4.93 | 3.64 | 5.19 | 5.50 | 4.67 | 8.08 | 4.56 | 4.18 | 1.76 | 0.42 | 2.70 | 8.61 | 5.64 | 10.55 | 4.40 |
| Enterprise value | 308Cr | 433Cr | 398Cr | 256Cr | 365Cr | 368Cr | 368Cr | 536Cr | 575Cr | 470Cr | 430Cr | 429Cr | 384Cr | 336Cr | 246Cr | 361Cr | 352Cr | 185Cr | 390Cr | 238Cr |
| Enterprise value to EBITDA ratio | 14.14 | 13.01 | 7.53 | 4.01 | 4.92 | 4.08 | 3.61 | 4.49 | 4.32 | 5.30 | 5.52 | 9.14 | 9.73 | 17.61 | 6.84 | 7.83 | 5.71 | 3.10 | 7.52 | 3.61 |
| Debt to equity ratio | 0.68 | 1.54 | 1.08 | 0.95 | 0.87 | 0.79 | 0.72 | 0.72 | 0.63 | 0.70 | 0.77 | 0.80 | 0.85 | 0.90 | 0.68 | 0.13 | 0.10 | 0.09 | 0.08 | 0 |
| Return on equity % | 66.53 | 58.29 | 49.69 | 38.62 | 25.54 | 22.65 | 17.30 | 16.70 | 15.30 | 1.12 | 0.38 | -4.13 | -8.18 | -8.23 | -3.05 | 17.07 | 9.69 | 5.90 | 6.01 | 8.64 |
Venus Remedies Ltd Ratios
The Venus Remedies Ltd Ratios page provides a complete fundamental analysis of Venus Remedies Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Venus Remedies Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is currently trading at ₹1616.30, with a market capitalization of ₹2181.83Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Venus Remedies Ltd remains a key stock for fundamental analysis using Venus Remedies Ltd Ratios.
Venus Remedies Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Venus Remedies Ltd P/E ratio currently stands at 8.84, making it one of the most tracked metrics in Venus Remedies Ltd Ratios.
Historically, the Venus Remedies Ltd P/E ratio has shown strong fluctuations:
- 2024: 8.84
- 2023: 15.31
- 2022: 8.15
- 2021: 8.82
- 2020: 5.49
The decline in Venus Remedies Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Venus Remedies Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.71.
Historical P/B trend:
- 2024: 0.71
- 2023: 0.89
- 2022: 0.47
- 2021: 0.82
Venus Remedies Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Venus Remedies Ltd P/S ratio currently stands at 0.62, an important part of Venus Remedies Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 0.62
- 2023: 0.74
- 2022: 0.39
- 2021: 0.60
A stable or declining Venus Remedies Ltd P/S ratio indicates cautious market sentiment.
Venus Remedies Ltd Price to Cash Flow Ratio (P/CF)
The Venus Remedies Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 4.40.
Historical Venus Remedies Ltd Price to Cash Flow Ratio:
- 2024: 4.40
- 2023: 10.55
- 2022: 5.64
- 2021: 8.61
- 2020: 2.70
The declining Venus Remedies Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Venus Remedies Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Venus Remedies Ltd EV currently stands at ₹238Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 238Cr
- 2023: 390Cr
- 2022: 185Cr
- 2021: 352Cr
Venus Remedies Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Venus Remedies Ltd EV/EBITDA ratio is currently 3.61, a key metric in Venus Remedies Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 3.61
- 2023: 7.52
- 2022: 3.10
- 2021: 5.71
Stable Venus Remedies Ltd EV/EBITDA indicates balanced valuation.
Venus Remedies Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Venus Remedies Ltd D/E ratio is currently 0, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0
- 2023: 0.08
- 2022: 0.09
- 2021: 0.10
Venus Remedies Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Venus Remedies Ltd ROE currently stands at 8.64%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 8.64
- 2023: 6.01
- 2022: 5.90
- 2021: 9.69
Declining ROE indicates pressure on profitability.
Venus Remedies Ltd Ratios Analysis Summary
The Venus Remedies Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Venus Remedies Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Venus Remedies Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.